MiniMed Group, Inc. (MMED) AI Stock Analysis

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for diabetes management. The company offers insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, consumables, supplies, and related software and services. It serves individuals requiring insulin therapy across all type 1 diabetes and select type 2 diabetes populations. Its product portfolio features Automated Insulin Delivery systems, Smart Multiple Daily Injection systems including InPen, Simplera Sync, or Guardian 4 sensors, and the CareLink software platform. Founded in 1983 and headquartered in Northridge, California, MiniMed operates as a subsidiary of Medtronic plc.

MiniMed expanded its revenue from $2.25B in FY2023 to $2.47B in FY2024, $2.71B in FY2025, and $3.10B in FY2026, recording a three-year revenue CAGR of 11.4%. Gross margin declined over this span from 58.3% in FY2023 to 54.2% in FY2026. Operating margin recovered to 1.6% in FY2026 after dropping to -7.4% in FY2025. Annual net losses deepened from -$96.0M in FY2023 to -$331.0M in FY2026, which represented a net margin of -10.7% and EPS of -$0.52. For the trailing twelve months through July 31, 2026, revenue stood at $3.22B with an operating margin of 0.5% and a quarterly revenue growth rate of 16.6%.

As of July 31, 2026, MiniMed held $207.0M in cash and short-term investments against $59.0M in total debt, resulting in net cash of $148.0M. The company had $4.72B in total assets, $3.62B in shareholders' equity, a current ratio of 1.81, and a debt-to-equity ratio of 0.02. Cash usage in FY2026 included $223.0M in capital expenditures. Operating cash flow was -$197.0M for FY2026, contributing to free cash flow of -$420.0M.

With a closing price of $17.49 on October 16, 2026, MiniMed had a market capitalization of $4.92B and an enterprise value of $5.57B. The stock traded at a price-to-sales multiple of 1.5x, below the median of 4.1x for its US-listed Healthcare peers. Its EV-to-EBITDA ratio stood at 92.9x, compared to the peer median of 12.0x, while its price-to-book ratio was 1.6x. Over the preceding 52-week period, MiniMed shares traded between a low of $10.65 and a high of $24.43.

Wall Street coverage consists of 11 Strong Buy, 1 Buy, 3 Hold, and 1 Sell ratings. The mean price target is $25.19, implying an upside of 44.0% from the last close of $17.49. For the fiscal year ending April 30, 2027, consensus estimates anticipate revenue of $3.44B and EPS of $0.70, representing projected EPS growth of 225.7%. For the subsequent fiscal year, 11 analysts project revenue of $3.73B, representing 8.4% growth, and EPS of $0.69.

This page is an AI-written research summary of MiniMed Group, Inc. (MMED). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MMED income statement, MMED balance sheet, MMED key metrics, MMED analyst forecast, MMED chart. See the MMED stock overview for the latest quote and news.